Quick Answer
vTv Therapeutics Inc. reported R&D Expense of $17.86 million for fiscal year 2025.
vTv Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $17.86M | +54.7% |
| 2024 | $11.55M | -15.1% |
| 2023 | $13.60M | +10.0% |
| 2022 | $12.36M | -7.3% |
| 2021 | $13.32M | +21.0% |
| 2020 | $11.02M | -27.1% |
| 2019 | $15.12M | -34.4% |
| 2018 | $23.04M | -41.9% |
| 2017 | $39.64M | -11.8% |
| 2016 | $44.95M | +65.0% |
| 2015 | $27.24M | +56.7% |
| 2014 | $17.38M | -22.0% |
| 2013 | $22.29M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.02M | +117.7% | +71.1% |
| June 30, 2025 | $4.10M | +19.3% | +45.0% |
| March 31, 2025 | $2.83M | +6.8% | -12.2% |
| September 30, 2024 | $3.22M | +14.2% | -6.3% |
| June 30, 2024 | $3.44M | -26.7% | +29.8% |
| March 31, 2024 | $2.65M | -32.8% | -6.2% |
| September 30, 2023 | $2.82M | -7.6% | -39.8% |
| June 30, 2023 | $4.69M | +112.7% | +19.0% |
- vTv Therapeutics Inc. showed an increase of +54.7% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, vTv Therapeutics Inc.’s r&d expense has declined by 19.9% (from $22.29 million to $17.86 million).
- The most recent figure is from vTv Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: